Matrix metalloproteinases: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{STRUCTURE_2clt| PDB=2clt | SIZE=300| SCENE=Matrix_metalloproteinase/Cv/1 |right| CAPTION= Human MMP1 complex with Ca+2 and Zn+2 ions, [[2clt]] }} | {{STRUCTURE_2clt| PDB=2clt | SIZE=300| SCENE=Matrix_metalloproteinase/Cv/1 |right| CAPTION= Human MMP1 complex with Ca+2 and Zn+2 ions, [[2clt]] }} | ||
| Line 6: | Line 5: | ||
== Endopeptidases involved in the degradation of the extracellular matrix== | == Endopeptidases involved in the degradation of the extracellular matrix== | ||
The matrix [[metalloproteases|metalloproteinases]] (MMPs) are zinc- and calcium dependent neutral endopeptidases involved in the degradation of the extracellular matrix and in tissue remodeling. Currently, approximately 27 MMPs are known. These have been grouped into subfamilies on the basis of their substrate specificity. Transcriptional regulation, zymogen activation and endogenous inhibitors control MMP activity under normal physiological conditions. Disturbance of this physiological balance may lead to an overexpression of MMPs followed by accelerated matrix degradation. The latter is associated with several pathologies including cancer cell invasion and metastasis, the loss of cartilage in osteoarthritis, rheumatoid arthritis, cardiovascular diseases, acute lung injury, chronic obstructive pulmonary disease, eye and skin diseases and periodontitis. As a consequence, the MMP family has emerged as an attractive pharmaceutical target. | The matrix [[metalloproteases|metalloproteinases]] (MMPs) are zinc- and calcium dependent neutral endopeptidases involved in the degradation of the extracellular matrix and in tissue remodeling. Currently, approximately 27 MMPs are known. These have been grouped into subfamilies on the basis of their substrate specificity. Transcriptional regulation, zymogen activation and endogenous inhibitors control MMP activity under normal physiological conditions. Disturbance of this physiological balance may lead to an overexpression of MMPs followed by accelerated matrix degradation. The latter is associated with several pathologies including cancer cell invasion and metastasis, the loss of cartilage in osteoarthritis, rheumatoid arthritis, cardiovascular diseases, acute lung injury, chronic obstructive pulmonary disease, eye and skin diseases and periodontitis.<ref>DOI:10.2174/157015909790031157</ref> As a consequence, the MMP family has emerged as an attractive pharmaceutical target. | ||
Blocking MMP gene transcription, proenzyme activation or active site-directed inhibitions are possible approaches for therapeutic intervention. | Blocking MMP gene transcription, proenzyme activation or active site-directed inhibitions are possible approaches for therapeutic intervention. | ||
==3D structures of MMP== | ==3D structures of MMP== | ||
[[Matrix metalloproteinase]] | [[Matrix metalloproteinase]] | ||